Trinity Biotech Senior Executives to Attend ATTD 2026 to Advance Collaborations Following Strong Progress in CGM Program
Rhea-AI Summary
Trinity Biotech (Nasdaq: TRIB) will attend ATTD 2026 in Barcelona to accelerate partnerships and commercialization planning for its next‑generation CGM platform, CGM+. Recent clinical performance supported the decision to advance the program into a pivotal clinical trial in 2026, with results indicating the system can meet modern CGM accuracy standards.
Executives will engage prospective collaborators across clinical research, technology integration, and commercial distribution ahead of the pivotal trial.
Positive
- Clinical data supported advancing the CGM+ program into a pivotal trial in 2026
- Leadership engagement at ATTD 2026 to accelerate partner and commercial discussions
- CGM+ reported performance consistent with industry accuracy standards for modern CGMs
- Development aligned with an AI-native healthcare analytics strategy for diabetes management
Negative
- None.
News Market Reaction – TRIB
On the day this news was published, TRIB gained 10.04%, reflecting a significant positive market reaction. Argus tracked a peak move of +5.8% during that session. Argus tracked a trough of -3.5% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $14M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TRIB is down 6.66% while key peers show mixed moves: IRIX +4.69%, NSYS +8.8%, AIMD +3.38%, PTHL +113.16%, and ADGM -2.04%. Momentum scanner shows only MYO moving up ~5.19%, suggesting TRIB’s decline is stock-specific rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 25 | Equity facility & update | Neutral | -0.0% | Standby Equity Purchase Agreement for up to $25M to fund growth initiatives. |
| Feb 20 | Nasdaq MVPHS notice | Negative | -1.6% | Nasdaq notice for falling below $15M market value of publicly held shares. |
| Feb 13 | Nasdaq bid-price notice | Negative | -0.6% | Non-compliance with $1.00 minimum bid price under Nasdaq Listing Rule 5450(a)(1). |
| Feb 10 | Manufacturing approval | Positive | +8.8% | Regulatory approval to offshore Uni-Gold HIV manufacturing supporting margin expansion goals. |
| Feb 10 | Product recognition | Positive | +8.8% | Premier Hb9210 HbA1c analyser awarded exclusive IFCC Gold Classification for 2026. |
Recent news reactions were consistently aligned with headline tone: Nasdaq non-compliance notices saw modest declines, while positive operational and product milestones, especially on Feb 10, coincided with strong +8.75% gains.
Over the past month, Trinity Biotech has balanced transformative initiatives with listing and financing pressures. On Feb 10, regulatory approval for offshored Uni‑Gold HIV manufacturing and IFCC Gold Classification for the Premier Hb9210 HbA1c analyser each aligned with +8.75% price moves. Subsequent Nasdaq non‑compliance notices on Feb 13 and Feb 20 and a $25 million SEPA on Feb 25 produced mild negative or flat reactions. Today’s CGM+ collaboration and conference update extends the diabetes‑focused innovation thread from these earlier announcements.
Market Pulse Summary
The stock surged +10.0% in the session following this news. A strong positive reaction would align with prior responses to operational wins, such as the dual +8.75% moves on Feb 10 after regulatory and product milestones. Advancing CGM+ toward a pivotal trial in 2026 and leveraging the ATTD 2026 conference for partnerships builds on that trajectory. However, existing Nasdaq compliance issues and recent equity financing structures from late February remain important context for assessing durability of any upside.
Key Terms
continuous glucose monitoring medical
wearable biosensors medical
ai-native technical
AI-generated analysis. Not financial advice.
- Company accelerating partner engagement ahead of pivotal clinical trial to be initiated in 2026
DUBLIN and WILSONVILLE, Ore., March 11, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that senior members of its executive leadership team will attend the ATTD 2026 (Advanced Technologies & Treatments for Diabetes) conference in Barcelona this week to progress strategic collaborations and commercialization plans for the Company’s next‑generation Continuous Glucose Monitoring (“CGM”) platform, CGM+.
The Company’s presence at ATTD follows compelling clinical performance data from its latest CGM technology developments, which formed the basis for Trinity Biotech’s decision to advance the program into a pivotal clinical trial in 2026. These results now provide strong evidence that the upgraded system can meet the industry standards for glucose measurement accuracy of modern CGMs. Ahead of this major development milestone, ATTD 2026 provides an important platform for the Company to accelerate partner engagement and prepare for the next phase of development and commercial readiness.
“Our CGM program has reached a meaningful inflection point, and ATTD is an ideal forum to deepen the partnerships necessary to bring this important innovation to market,” said John Gillard, Trinity Biotech President & Chief Executive Officer. “With pivotal clinical trial preparations underway, our team will be engaging with prospective collaborators across clinical research, technology integration, and commercial distribution as we build momentum with this exciting platform.”
Trinity Biotech’s CGM+ platform is being developed as part of the Company’s broader strategy to create integrated, AI-native healthcare analytics that support data-driven health solutions to enhance the management of diabetes and metabolic health worldwide.
For more information on CGM+ please visit our dedicated website https://cgm.trinitybiotech.com/
Forward-Looking Statements
This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, the impact of the spread of COVID-19 and its variants, the possible pause and/or disruption in U.S. Government funding for HIV tests produced by Trinity Biotech, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2024 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.
About Trinity Biotech
Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.
| Contact: | Trinity Biotech plc | RedChip Companies Inc. |
| Gary Keating, PhD | Dave Gentry, CEO | |
| (353)-1-2769800 | (1)-407-644-4256 | |
| (1)-800-RED-CHIP (733-2447) | ||
| TRIB@redchip.com |
FAQ
What did Trinity Biotech (TRIB) announce about its CGM+ program at ATTD 2026?
When will Trinity Biotech (TRIB) start the pivotal clinical trial for CGM+?
How did Trinity Biotech describe CGM+ clinical performance and accuracy?
What will Trinity Biotech executives do at the ATTD 2026 conference for TRIB shareholders?
How does CGM+ fit into Trinity Biotech's broader strategy for TRIB?
Where can investors find more information about Trinity Biotech's CGM+ program (TRIB)?
